Latest Recruitment News

Neurizon Therapeutics has completed enrolment for Regimen I of its HEALEY ALS Platform Trial in under five months, speeding up topline data release to late Q2 2027 and materially de-risking its lead clinical program.

Dimerix has acquired DMX-652, a Phase 2-ready oral drug candidate targeting acute kidney injury, expanding its renal disease portfolio. The acquisition includes patent rights, an FDA-approved trial protocol, and funding to initiate clinical development.

Ava Risk Group expects FY2026 revenue around $29 million, below prior guidance, due to delayed orders mainly in the Middle East and North America. Despite this, sales intake exceeded revenue, underpinning a strong backlog and positive EBITDA.

EMVision Medical Devices has hit key enrolment milestones in its pivotal brain scanner trial, expanded clinical endpoints, and maintained a strong cash position with $17.1 million on hand.

Freehill Mining’s aggregates business posted a record $1.36 million in quarterly sales, up 47% from the prior quarter, driven by plant improvements and a broadening customer base. June alone saw a record $496,000 in sales, underpinning the company’s copper project ambitions.

Medallion Metals is fast-tracking gold production at its Forrestania Gold Project by launching an Early Production Strategy in Q4 2026, nearly nine months ahead of schedule. This move leverages existing infrastructure to generate cashflow and de-risk the upcoming Ravensthorpe ore processing.

Pantoro Gold's FY2026 gold output fell below expectations due to contractor and labour shortages, prompting a strategic operational review. The company targets 90,000 to 105,000 ounces in FY2027 with a stabilisation-first approach and significant investments in new ore sources and infrastructure.

The a2 Milk Company faced significant supply chain disruptions in its China infant formula segment during late FY26, causing a 14% sales decline in that category. Despite this, overall revenue rose 12% on FY25, supported by strong performances in other product lines and improved margins.

Nexalis Therapeutics has ended funding negotiations with Point8 Capital after failing to secure a formal agreement, while successfully completing its IRX-616a Phase 1 trial with no serious adverse events. The company is reassessing clinical priorities amid funding uncertainty.

Excite Technology Services has raised $3.26 million through a share placement priced at 0.6 cents each, accompanied by free-attaching options pending shareholder approval. The Managing Director will convert $500,000 of debt into equity on matching terms.

Racura Oncology has secured Bellberry HREC approval for its HARNESS-1 lung cancer trial, enabling expansion to additional Australian sites including Chris O’Brien Lifehouse and Austin Health, setting the stage for accelerated patient enrolment.

Telix Pharmaceuticals has gained FDA alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer, setting the stage for U.S. enrolment pending regulatory approval.